These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 30464578)
1. Practical management of opioid rotation and equianalgesia. Treillet E; Laurent S; Hadjiat Y J Pain Res; 2018; 11():2587-2601. PubMed ID: 30464578 [TBL] [Abstract][Full Text] [Related]
2. A Comparison of Institutional Opioid Equianalgesia Tools: A National Study. Wen RY; Atayee RS; Edmonds KP J Palliat Med; 2022 Nov; 25(11):1686-1691. PubMed ID: 35559657 [No Abstract] [Full Text] [Related]
3. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study. Clemens KE; Klaschik E Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302 [TBL] [Abstract][Full Text] [Related]
4. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature. Jackson LD; Wortzman R; Chua D; Selby D J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183 [TBL] [Abstract][Full Text] [Related]
5. Pediatric palliative care: use of opioids for the management of pain. Zernikow B; Michel E; Craig F; Anderson BJ Paediatr Drugs; 2009; 11(2):129-51. PubMed ID: 19301934 [TBL] [Abstract][Full Text] [Related]
6. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? Ripamonti C; Groff L; Brunelli C; Polastri D; Stavrakis A; De Conno F J Clin Oncol; 1998 Oct; 16(10):3216-21. PubMed ID: 9779694 [TBL] [Abstract][Full Text] [Related]
7. [Opioid switch and change of route of administration in cancer patients treated by morphine]. Michenot N; Rostaing S; Baron L; Faure S; Jovenin N; Hubault P; Delorme T; Collin E; Filbet M; Chvetzoff G; Delorme C; Minello C; Magnet M; Ammar D; Krakowski I; Poulain P Bull Cancer; 2018 Nov; 105(11):1052-1073. PubMed ID: 30274680 [TBL] [Abstract][Full Text] [Related]
8. Opioid equianalgesic tables: are they all equally dangerous? Shaheen PE; Walsh D; Lasheen W; Davis MP; Lagman RL J Pain Symptom Manage; 2009 Sep; 38(3):409-17. PubMed ID: 19735901 [TBL] [Abstract][Full Text] [Related]
9. Methadone Switching for Cancer Pain: A New Classification of Initiation Protocols, Based on a Critical Literature Review. Treillet E; Giet O; Picard S; Laurent S; Seresse L J Palliat Med; 2021 Dec; 24(12):1884-1894. PubMed ID: 34851186 [No Abstract] [Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
11. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811 [TBL] [Abstract][Full Text] [Related]
12. Why equianalgesic tables are only part of the answer to equianalgesia. McPherson ML Ann Palliat Med; 2020 Mar; 9(2):537-541. PubMed ID: 32233628 [TBL] [Abstract][Full Text] [Related]
13. Inconsistencies in opioid equianalgesic ratios: clinical and research implications. O'Bryant CL; Linnebur SA; Yamashita TE; Kutner JS J Pain Palliat Care Pharmacother; 2008; 22(4):282-90. PubMed ID: 21923312 [TBL] [Abstract][Full Text] [Related]
14. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients. Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751 [TBL] [Abstract][Full Text] [Related]
16. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Mercadante S; Caraceni A Palliat Med; 2011 Jul; 25(5):504-15. PubMed ID: 21708857 [TBL] [Abstract][Full Text] [Related]
17. Modified glasgow prognostic score predicting high conversion ratio in opioid switching from oral oxycodone to transdermal fentanyl in patients with cancer pain. Jia SS; Shang L; Li ME; Zhao DM; Xu WH; Wang YQ Int J Clin Exp Med; 2015; 8(5):7606-12. PubMed ID: 26221306 [TBL] [Abstract][Full Text] [Related]
18. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453 [TBL] [Abstract][Full Text] [Related]
19. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Lawlor P; Turner K; Hanson J; Bruera E Pain; 1997 Aug; 72(1-2):79-85. PubMed ID: 9272790 [TBL] [Abstract][Full Text] [Related]